Search
Temocillin
go.drugbank.com/drugs/DB12343ApprovedInvestigationalWithdrawnTemocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.
Fucoxanthin
go.drugbank.com/drugs/DB15462InvestigationalIn vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. … Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).
ABT-560
go.drugbank.com/drugs/DB06093ExperimentalABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.
ANA975
go.drugbank.com/drugs/DB06490ExperimentalANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.
Synonyms: AN 975Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
go.drugbank.com/drugs/DB16431ExperimentalRegarding this vaccine specifically, it stimulates the immune system to produce anti-receptor binding domain antibodies[A226593].
Bisphosphocin Nu-3
go.drugbank.com/drugs/DB16015InvestigationalBisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).
Resiniferatoxin
go.drugbank.com/drugs/DB06515InvestigationalResiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission
BMS-488043
go.drugbank.com/drugs/DB05532ExperimentalBMS-488043 has been investigated as an anti-HIV agent.
AMGN-0007
go.drugbank.com/drugs/DB06511ExperimentalRecombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
Olvimulogene nanivacirepvec
go.drugbank.com/drugs/DB16268InvestigationalOlvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).